Tourmaline Bio, Inc. — Director's Dealing 2021

May 7, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Talaris Therapeutics, Inc. (TALS)
CIK: 0001827506
Period of Report: 2021-05-06

Reporting Person: Ildstad Suzanne (Director, Chief Scientific Officer, 10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	4806446	Direct
Common Stock	654205	Indirect
Common Stock	654205	Indirect

Footnotes

F1: These shares are held in a trust for the benefit of the reporting person's son. The reporting person's son is co-trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

F2: These shares are held in a trust for the benefit of the reporting person's daughter. The reporting person's daughter is co-trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.